Core Insights - Biodexa Pharmaceuticals PLC has announced the brand name "Serenta" for its upcoming Phase 3 clinical study in Familial Adenomatous Polyposis (FAP) [1][2] - The company has launched a dedicated website, www.serentatrial.com, to provide information and resources for patients, caregivers, and healthcare professionals [1][2] Company Overview - Biodexa is a clinical stage biopharmaceutical company focused on developing innovative products for diseases with unmet medical needs, with its lead programs including eRapa for FAP and Non-Muscle Invasive Bladder Cancer, tolimidone for type 1 diabetes, and MTX110 for aggressive rare/orphan brain cancer [4][8] - eRapa is a proprietary oral tablet formulation of rapamycin, an mTOR inhibitor, designed to improve bioavailability and reduce toxicity associated with existing rapamycin formulations [3][5] - The company utilizes proprietary drug delivery technologies to enhance the bio-distribution of its medicines [8]